Georgetown Lombardi Comprehensive Cancer Center

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Retrieved on: 
Tuesday, October 31, 2023
Haemophilia, Factor VIII, European Journal, PROPEL, PROTECT, Exercise, Georgetown University Medical Center, VIII, Georgetown Lombardi Comprehensive Cancer Center, Efmoroctocog alfa, Patient, Pharmaceutical industry, Dentistry

The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.

Key Points: 
  • The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.
    Dr Kessler commented, "This MAIC exercise provides important comparative data on the efficacy and consumption of various recombinant FVIII products in adults with haemophilia A on personalised prophylaxis.
  • The results can be considered by clinicians and patients when treatment decisions are being made."
  • MAICs are a way of comparing the efficacy of different medical interventions or products in the absence of head-to-head randomised trials3.
  • In addition, a short video summarising the results is available in the online version of the article.

Ralph Lauren Details Progress on Social and Environmental Goals in 2023 Global Citizenship & Sustainability Report

Retrieved on: 
Tuesday, June 20, 2023
Online Retail, Luxury, Professional Services, Other Consumer, Specialty, Department Stores, Environmental, Social and Governance (ESG), Fashion, Catalog, Retail, Consumer, RL, Workforce, Georgetown Lombardi Comprehensive Cancer Center, Mineral, Timeless, Sustainability reporting, Woman, Ralph Lauren Corporation, Science, NYSE, Plant, Coal, Nature, Parity, Sustainability, Incineration, Design, Environment, Communications officer, Fashion design, Renewable energy

Ralph Lauren Corporation (NYSE:RL) today published its 2023 Global Citizenship & Sustainability Report, emphasizing the Company’s ongoing commitment to creating timeless products that are made to live on responsibly, using materials in ways that reduce its products’ environmental impact, and supporting people within its workforce, supply chain and communities.

Key Points: 
  • Ralph Lauren Corporation (NYSE:RL) today published its 2023 Global Citizenship & Sustainability Report, emphasizing the Company’s ongoing commitment to creating timeless products that are made to live on responsibly, using materials in ways that reduce its products’ environmental impact, and supporting people within its workforce, supply chain and communities.
  • The 2023 report outlines progress across the Company’s Citizenship & Sustainability approach, Timeless by Design , which ensures timelessness is embedded from inspiration through to products’ every use and reuse across generations.
  • “Ralph’s vision of timelessness is apparent in the beautiful products we create, and it’s our commitment to ensure this vision is carried into how we create and address our impact on the world,” said Katie Ioanilli, Chief Global Impact & Communications Officer, Ralph Lauren Corporation.
  • “Our approach is rooted in science, ambitious goals, collaboration and innovation that, together, will enable us to continue to inspire people to live the life of their dreams.”
    As part of its Timeless by Design strategy, the Company continued over the past year to advance on its commitments across three pillars: Create with Intent, Protect the Environment and Champion Better Lives.

CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE

Retrieved on: 
Thursday, June 1, 2023
Triple-negative breast cancer, Georgetown Lombardi Comprehensive Cancer Center, Receptor (biochemistry), Clinical trial, Cancer, Woman, Attention, Dementia, MACP, Georgetown University, Trial of the century, Patent, Patient, Breast cancer, Risk, Recurrence, Memory, Metastasis, Pharmaceutical industry

WESTON, Fla., June 1, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, today announced that it has obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent or alleviate cancer-treatment related cognitive decline. This exclusive worldwide license expands Cantex's existing robust azeliragon composition of matter patent, its overall intellectual property portfolio and additional regulatory exclusivities.

Key Points: 
  • This exclusive worldwide license expands Cantex's existing robust azeliragon composition of matter patent, its overall intellectual property portfolio and additional regulatory exclusivities.
  • Cancer-related cognitive decline involves problems with memory, attention, concentration, and executive functioning that may result from some cancer treatments.
  • Georgetown is currently enrolling patients in a pilot clinical trial of Cantex's azeliragon in women with breast cancer receiving neoadjuvant chemotherapy.
  • Marc Lippman is a co-inventor on a patent application that has been filed by Georgetown University related to the technology described.

COTA, Inc. Forms Strategic Real-World Data Research Partnership with the Clinical Research Data Sharing Alliance

Retrieved on: 
Tuesday, January 31, 2023
Software, Research, Networks, Pharmaceutical, Oncology, Data Management, Technology, Health Technology, Clinical Trials, Science, Biotechnology, Health, Organization, Trust, CRDSA, Drug development, University of Texas Southwestern Medical Center, Patient, Clinical trial, University, Food, Friends of Cancer Research, Privacy, University of Rochester, Lung cancer, Friends, Georgetown Lombardi Comprehensive Cancer Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NSCLC, Cancer, Pharmaceutical industry

COTA, Inc. , an oncology real-world data and analytics company, today announced its membership in the Clinical Research Data Sharing Alliance (CRDSA), a nonprofit, cross-industry alliance of biopharma companies, data sharing platforms, academic institutions, and service and technology partners.

Key Points: 
  • COTA, Inc. , an oncology real-world data and analytics company, today announced its membership in the Clinical Research Data Sharing Alliance (CRDSA), a nonprofit, cross-industry alliance of biopharma companies, data sharing platforms, academic institutions, and service and technology partners.
  • Member organizations collaborate to accelerate the discovery and delivery of life-saving therapies to patients through the use of high-quality clinical trial and real-world data.
  • As the newest member of CRDSA, COTA will participate in the Alliance’s steering committee and the Innovative Trial Design Working Group.
  • One of the goals of this project is to explore the complementary use of real-world and clinical trial data in research and drug development.

BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer

Retrieved on: 
Wednesday, February 8, 2023
Society, Prostate cancer, SWOG, Francis, Yale School of Medicine, National Cancer Institute, Pancreatic cancer, Yale school, Clinical Science (journal), Cancer, NCI, Clinical Genitourinary Cancer, RSVP, Therapy, Baozou Big News Events, Georgetown University Medical Center, University, Patient, Artificial intelligence, Prostate, ASCO, Urology, University of California, San Francisco, Testicular cancer, KOL, Associate, Kidney, Georgetown Lombardi Comprehensive Cancer Center, Research, UCSF, Medical imaging, Medicine, HAVEN, SCNC

SCNC represents a rare, underserved, growing patient population, with SCNC cases increasing due to earlier and more widespread use of androgen receptor inhibitors.

Key Points: 
  • SCNC represents a rare, underserved, growing patient population, with SCNC cases increasing due to earlier and more widespread use of androgen receptor inhibitors.
  • In 2022, there were an estimated 268,5001 new prostate cancer patients, with approximately 10,740 patients progressing to SCNC.
  • To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.
  • Dr. Louis M. Weiner is Director of Georgetown Lombardi Comprehensive Cancer Center, one of 53 National Cancer Institute (NCI)-designated comprehensive cancer centers in the United States.

An Impressive Start For The 2023 Washington, D.C. Auto Show

Retrieved on: 
Tuesday, January 24, 2023
Petro, Policy, Ford Motor Company, Dog, News, Washington Convention Center, U.S. News & World Report, EV, Public policy, Lamborghini, Hospital, Money, Auto, Hand of Hope (photography), Research, Sale, Polestar, SE, Convention center, Bentley, Walter, Toyota Prius, Georgetown Lombardi Comprehensive Cancer Center, Hyundai, Nightclub, MD, Subaru

Washington, D.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- The 2023 Washington, D.C. Auto Show opened last Thursday to policy leaders, automotive experts, and media partners during the highest attended Public Policy Day in recent years.

Key Points: 
  • Washington, D.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- The 2023 Washington, D.C. Auto Show opened last Thursday to policy leaders, automotive experts, and media partners during the highest attended Public Policy Day in recent years.
  • “Our Public Policy Day is centered at the intersection of automotive regulation and technology development,” said John O’Donell.
  • The Washington, D.C. Auto Show remains open to the public all week long through Sunday, January 29.
  • Tickets are on sale now and can be purchased on the Auto Show’s website at www.washingtonautoshow.com .

The Washington, D.C. Auto Show and Washington Area Hyundai Dealers Team up to Support Georgetown Lombardi and Children’s National Hospital Through “Hyundai Hands On Hope” Contest

Retrieved on: 
Wednesday, January 18, 2023
National Cancer Institute, American Cancer Society, Nursing, Hyundai Motor America, Washington Auto Show, MD, Ewing's sarcoma, Partnership, Healthcare in Washington, D.C., Contest, Cancer, Hope, Hyundai, Georgetown, MedStar Health, U.S. News & World Report, Walter E. Washington Convention Center, Georgetown University Medical Center, Degenerative disease, Research, Human, Washington Convention Center, Walter, Hackensack Meridian Health, News, Clinical trial, Georgetown Lombardi Comprehensive Cancer Center, Children's National Hospital, NCI, NCI-designated Cancer Center, Child, Hospital, Diagnosis, Harwell Science and Innovation Campus, L Street Bridge, Health, Motor vehicle, Medicine, Birth control, Machine tool, Wheel, D.C, NW

Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”

Key Points: 
  • Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”
    Six contestants will compete for a brand-new 2023 Hyundai IONIQ5 over the 44-hour contest period.
  • For Georgetown Lombardi, its grant will be put towards funding pediatric cancer research.
  • "Every 36 minutes a child is diagnosed with pediatric cancer,” shared Kevin Reilly, President of The Washington Area Hyundai Dealers.
  • A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington, D.C., area.

OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2022 Luminary Awards in Gastrointestinal Cancers

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, The Westin Georgetown, Washington, D.C., Cure, Gastrointestinal cancer, Georgetown Lombardi Comprehensive Cancer Center, Research, Education, Health, GI, Cancer, Science, Patient, Pharmaceutical industry, Medicine

CRANBURY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- OncLive, the nations leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers, part of the Georgetown Lombardi Comprehensive Cancer Center, today announced the five winners of the 2022 Luminary Awards in GI Cancers.

Key Points: 
  • CRANBURY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- OncLive, the nations leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers, part of the Georgetown Lombardi Comprehensive Cancer Center, today announced the five winners of the 2022 Luminary Awards in GI Cancers.
  • The winners of the 2022 Luminary Awards are very deserving, and we are grateful for their dedication to the field.
  • The 2022 Luminary Award winners are:
    Held in conjunction with the 13th Annual Ruesch Center Symposium, The Luminary Awards in GI Cancers reception will be held in person at the Westin Georgetown from 5-9 p.m.
  • The Ruesch Center for the Cure of Gastrointestinal Cancers is part of the Georgetown Lombardi Comprehensive Cancer Center.

Practice Changing Study Highlights Value of Starting Immunotherapy Before Targeted Therapies in Patients with BRAF-Mutated Melanoma

Retrieved on: 
Tuesday, October 4, 2022
DREAM, Nation, Cancer, MEK, Hospital, American Journal of Clinical Oncology, Melanoma, American Cancer Society, Mortality, NCI, Neoplasm, Physician, Ipilimumab, Immunotherapy, Survival, Research, Disease, New Jersey-New York 7 Conference, NCI-designated Cancer Center, Clinical trial, Hackensack Meridian Health, New, Multimedia, Protein, Nursing, BRAF, Patient, Progression-free survival, September 27, View, Annual report, Mutation, Immune system, MedStar Health, CI, Georgetown Lombardi Comprehensive Cancer Center, Hackensack Meridian School of Medicine, Strathcona County, Georgetown, Journal, Oncology, Nivolumab, Education, Aftercare, Diagnosis, MedSTAR, Dabrafenib, III, Pharmaceutical industry, Vaccine

Targeted medications and immunotherapy have become standard care for people with advanced melanoma.

Key Points: 
  • Targeted medications and immunotherapy have become standard care for people with advanced melanoma.
  • Starting in 2015, 265 patients with metastatic melanoma were randomly assigned to one of two groups.
  • One group started treatment with combination ipilimumab and nivolumab immunotherapy, and the second group began with the targeted therapies dabrafenib and trametinib.
  • Two-year overall survival was 72% among patients who received combination immunotherapy first versus 52% for those who took the two targeted therapies as initial treatment.

HYUNDAI HOPE ON WHEELS AND MEMBERS OF CONGRESS HONOR NATIONAL CHILDHOOD CANCER AWARENESS MONTH

Retrieved on: 
Thursday, September 22, 2022
Hyundai Santa Fe, COG, Child, Awareness, Childhood cancer, National Childhood Cancer Awareness Month, Hope, Organization, Children's Oncology Group, Hyundai Motor America, Cancer, Physician, Goal, Paint, Georgetown Lombardi Comprehensive Cancer Center, Research, Hospital, Congress, Multimedia, Hyundai, Legislation, Disease, Pharmaceutical industry, Toy, Heavy equipment, Wheel

"Together with Hyundai Hope On Wheels, Hyundai builds more than cars; it builds families, communities, and hope.

Key Points: 
  • "Together with Hyundai Hope On Wheels, Hyundai builds more than cars; it builds families, communities, and hope.
  • "September is National Childhood Cancer Awareness Month, a time so critical to our goals to raise awareness, drive hope, and move closer to a cure.
  • Hyundai Hope On Wheels is a 501(c)(3) nonprofit organization that is committed to finding a cure for childhood cancer.
  • Since its inception, Hyundai Hope On Wheels has pledged $200 million in support of more than 1,000 childhood cancer research grants.